Skip to main content

Table 1 Patient Demographics and Baseline Characteristics (Safety Population)

From: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Baseline Characteristic

Total

Number of patients in safety population

38

Age, years

65.6 (6.4)

Male, n (%)

22 (57.9)

White, n (%)

38 (100)

Body mass index, kg/m2

27.7 (3.5)

Smoking status, n (%)

 Current

14 (36.8)

 Former

24 (63.2)

Smoking consumption, pack-years

45.4 (26.8)

COPD severity, n (%)

 Moderate

22 (57.9)

 Severe

16 (42.1)

Duration of COPD, years

9.5 (5.9)

Number of COPD exacerbations in previous 12 months, n (%)

 1

8 (21.1)

 2

6 (15.8)

 3

2 (5.3)

Postbronchodilator % predicted FEV1

52.0 (12.5)

Postbronchodilator FEV1/FVC

45.8 (10.2)

Bronchial reversibility, %

19.89 (13.72)

FEV1 absolute reversibility, L

0.217 (0.124)

  1. COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
  2. Data are mean (standard deviation) unless otherwise stated